Home Antibody All anti-GDF15 antibodies
Also for GDF15 (NM_004864)
|This affinity purified antibody was prepared by repeated immunizations with a synthetic peptide corresponding to a region near the amino terminal end of human NAG-1 protein. A residue of cysteine was added to facilitate coupling to KLH.|
||ELISA: 1:10,000, WB: 2,000-10,000, IHC: User Optimized
|0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2|
|Non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. Induced expression of NAG-1 results in stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.
|Homo sapiens growth differentiation factor 15 (GDF15)|
|GDF-15; MIC-1; MIC1; NAG-1; PDF; PLAB; PTGFB|
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
In this sandwich ELISA, NAG-1 was captured from human serum using the following antibodies (see Related Products below): anti-NAG-1/GDF15 (C terminal specific), anti-NAG-1/GDF15 (N terminal specific (PAN)), anti-NAG-1/GDF15 (H-variant) and anti-NAG-1/GDF15 (D-variant) polyclonal antibodies. Micro titer plates were coated with capture antibody at 1 µg/mL. Control plates received PBS only (data not shown). After overnight incubation and blocking, independent experiments using 20 random normal human sera were performed. Neat normal sera were applied and incubated for 1 h at 37 °C. After washing, HRP conjugated anti-NAG-1/GDF15 (C terminal specific) antibody was added for detection at 100 µL per well at 1 µg/mL. Following further incubation for 1 hr at 37°C, the plates were washed and TMBE was added as an HRP substrate for 30 min. The reaction was stopped by 1 M H2SO4 and values were measured at 450nm.